Search Results
Your search for ,maY matches 17054 pages
Showing 15351 - 15400CancerCare® Welcomes Christine Verini, RPh, as Chief Business Development Officer
CancerCare®, a national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to welcome Chief Business Development Officer Christine Verini, RPh. In her role, Ms. Verini will serve as a key member of CancerCare’s Executive Leadership Team,...
Many Patients Do Not Accurately Recall Important Colonoscopy Details as Time Lapses
As time lapses, many patients who have undergone a colonoscopy become less and less likely to recall when and where they last had the procedure performed, who the doctor was who performed it, whether polyps were found, and, if so, the number and size of those polyps, according to new study results...
Alternative Therapies: Knowledge Is Power, but Consider the Source
The use of dietary supplements and other complementary and “alternative” therapies by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about complementary therapies can be...
Important Research in the Palliative Care of Patients With Cancer
The emphasis at this year’s Palliative Care in Oncology Symposium, held earlier this month in Boston, was on patient-centered care throughout the cancer continuum. The meeting attracted more than 650 attendees and included six general sessions featuring best practices in communication,...
Delays in Drug Approval Are Deadly, Highlighting the Need for Improved Regulatory Efficiency
Researchers have determined just how many lives are lost when effective investigational drugs are not approved in a timely manner. These delays in the process of anticancer drug approvals result in thousands of premature deaths each year, according to an analysis presented at the 16th World...
MRI Improves Breast Cancer Detection in Women at Average Risk
Magnetic resonance imaging (MRI) screening of women at average risk for breast cancer achieved a mean additional cancer yield of 15.8 cases per 1,000 women, greatly surpassing yields for supplemental digital breast tomosynthesis (1.25 per 1,000) or supplemental ultrasound (4.1 per 1,000). The...
Aromatase Inhibitors May Decrease Risk of Contralateral Breast Cancer in BRCA Mutation–Positive Patients
Given that BRCA1 and BRCA2 mutation carriers have an estimated 40% to 85% lifetime risk of breast cancer and an increased risk of developing contralateral breast cancer, risk reduction in this population remains essential. According to a study presented at the 2015 Breast Cancer Symposium, use of...
Expert Point of View: Clifford Hudis, MD
Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, said the findings suggest there is essentially no meaningful benefit from chemotherapy in the recurrence score low-risk subset. “It is clinically appropriate to offer endocrine therapy...
TAILORx: Chemotherapy Not Necessary for Women With a Low Recurrence Score
The long-awaited first results are in from the TAILORx study, showing that patients with early breast cancer considered at low risk for recurrence can forgo chemotherapy and be treated with endocrine therapy alone.1 “Women with axillary node-negative, estrogen receptor–positive, HER2-negative...
Expert Point of View: Enrique Grande, MD
Enrique Grande, MD, Head of the Endocrine and Genitourinary Tumors Section of the Medical Oncology Service at Ramon y Cajal University Hospital, Madrid, discussed the NETTER-1 and RADIANT-4 studies at the Presidential Session of the 2015 European Cancer Congress. “There is now a stronger rationale...
Atezolizumab Makes Inroads in Non–Small Cell Lung Cancer
The anti–PD-L1 (programmed cell death-ligand 1) antibody atezolizumab (formerly known as MPDL3280A) achieved encouraging outcomes in patients with non–small lung cancer (NSCLC) in two different trials: POPLAR1 and BIRCH.2 PD-L1 has emerged as a predictive biomarker for atezolizumab response in both ...
Ovarian Suppression During Chemotherapy Preserves Fertility in Young Women With Breast Cancer
Several studies have addressed the risks and benefits of ovarian suppression during chemotherapy for breast cancer in women of childbearing age. A new meta-analysis of randomized trials found that it prevented premature ovarian failure and was associated with a higher number of pregnancies post...
Discussing Financial Toxicity With Patients Who Have Cancer
Patient: “Doc, how much are these drugs going to cost me?” Physician: “They are expensive, and you can see our financial counselor to help you understand the costs.” Cancer care is not a black-and-white endeavor, and costs are considered a distasteful subject to be passed over in tactful silence. ...
Expert Point of View: Cora N. Sternberg, MD, FACP
Cora N. Sternberg, MD, FACP, Chief of Medical Oncology at San Camillo Forlanini Hospital in Rome, Italy, formally discussed CheckMate 025 at the Presidential Session of the 2015 European Cancer Congress as well as findings from the METEOR trial of cabozantinib (Cometriq) in metastatic renal cell...
FDA Approves First Oncolytic Viral Therapy in the United States
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma...
ASH Honors Aaron J. Marcus, MD, Posthumously With Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) will recognize the late Aaron J. Marcus, MD, of Weill Cornell Medical College and the Veterans Affairs New York Harbor Healthcare System with the 2015 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Marcus, who passed away in May 2015,...
Tamoxifen Use and Access to Fertility-Preservation Options Among Premenopausal Women With Breast Cancer
A multivariable analysis of clinical factors associated with tamoxifen use among premenopausal women with hormone receptor–positive breast cancer showed that fertility preservation was a significant factor and “the only predictor of both noninitiation and early cessation” of tamoxifen. “Among...
ASCO-Endorsed ASTRO Guidelines: Searching for Consensus on Radiotherapy for Endometrial Cancer
Endometrial cancer is the most common gynecologic cancer, but there has been little consensus about the appropriate indications for adjuvant therapy. One reason for the lack of consensus is the absence of randomized studies in endometrial cancer that report an overall survival benefit. This may be...
ASCO Endorses ASTRO Guideline on Postoperative Radiation Therapy for Endometrial Cancer
As reported in the Journal of Clinical Oncology by Larissa A. Meyer, MD, MPH, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) guideline on postoperative radiation therapy for endometrial cancer.1 The ASCO clinical practice guideline...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Equanimity
The following essay by S. Vincent Rajkumar, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. It was...
NCI Names Thomas Kensler, PhD, Outstanding Investigator
Thomas Kensler, PhD, Professor of Pharmacology and Chemical Biology and Co-Leader for the Cancer Epidemiology and Prevention Program at the University of Pittsburgh Cancer Institute (UPCI), was awarded a $6.3 million Outstanding Investigator Award from the National Cancer Institute (NCI). This new...
Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Question 1: What is next best step in the management of this patient? Correct Answer: C. Ophthalmoscopy/slit lamp examination. Expert Perspective Ophthalmic involvement should be sought by noninvasive procedures such as slit lamp examination and ophthalmoscopy and abnormal findings must be...
2015 Oncology Meetings
NOVEMBER Best of ASTRONovember 13-14 • San Diego, California For more information: www.astro.org/Meetings-and-Events/2015-Best-of-ASTRO/Index.aspx 2015 Oncologic Emergency Medicine Conference November 13-14 • Houston, Texas For more information:...
A Chemist Exposes Dangerous Chemicals
Bookmark Title: Pick Your Poison: How Our Mad Dash to Chemical Utopia Is Making Lab Rats of Us All Author: Monona Rossol Publisher: John Wiley & Sons Publication date: October 2015 Price: E-book, 210 pages Monona Rossol is a chemist and “industrial hygienist” who is a frequent contributor to...
A Pandemic’s Story of Tragedy and Success
Bookmark Title: AIDS Between Science and Politics Author: Peter Piot Publisher: Columbia University Press Publication date: May 2015 Price: $29.95; hardcover, 216 pages AIDS is a global phenomenon that recognizes neither national boundaries nor social strata. The AIDS pandemic was one of the...
New Study Indicates Key Differences Between Trial Enrollees and Patients Receiving Treatments
A new article published in the Journal of Oncology Practice evaluates differences between the treatment of patients with metastatic renal cell cancer who participated in clinical trials vs those who received the same therapy in routine clinical practice. Nearly 40% of patients in the real-world...
Management of Aromatase Inhibitor–Induced Musculoskeletal Symptoms: A Physiatric Approach
Aromatase inhibitors have demonstrated efficacy in reducing the risk of breast cancer recurrence in hormone receptor–positive patients, but medication compliance can be limited by uncomfortable side effects, including musculoskeletal pain and dysfunction. Musculoskeletal symptoms have been reported ...
Geriatric Oncology in Europe: A Commitment to Improving Cancer Care for Older Patients
In Europe, the field of geriatric oncology has a long history of development, and its organization and implementation continue to improve every day. This would not have happened without the strong commitment of national authorities to health policies, a critical success factor. Four Missions In...
Why Melanoma Rates Are Increasing in Adolescents and Young Adults, Especially Among Females
The incidence of melanoma among children, adolescents, and young adults has reached epidemic proportions, increasing more than 250% over the past 4 decades, with young females at highest risk for the deadly cancer, according to a study1 by researchers at Roswell Park Cancer Institute in Buffalo,...
Survival and Bevacizumab in Early Breast Cancer: Time to Reconsider?
In metastatic HER2-negative breast cancer, several trials have shown that the addition of the anti–vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) to different chemotherapy regimens significantly improved response rates and progression-free survival by various...
Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early HER2-Negative Breast Cancer
The phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel + anthracycline-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early...
ASCO Recommendations for Use of White Blood Cell Growth Factors: What Remains the Same and What Has Been Modified
Neutropenic complications remain the main dose-limiting toxicity of cancer chemotherapy treatment and are associated with considerable morbidity, mortality, and costs.1 Although patients who have experienced a prior neutropenic event are at increased risk of subsequent events, several studies have...
ASCO Clinical Practice Guideline Update: Recommendations for the Use of White Blood Cell Growth Factors
ASCO has issued a clinical practice guideline update on use of hematopoietic colony-stimulating factors, as reported in the Journal of Clinical Oncology by Thomas J. Smith, MD, FACP, FASCO, FAAHMP, and colleagues.1 This update to the ASCO 2006 guideline was based on a systematic review of...
NCCN Unveils Graphic Evidence Blocks to Guide Decision-Making
Treatment decision-making for oncologists and their patients may become simpler through the use of graphic NCCN Evidence Blocks™, which were unveiled at the NCCN 10th Annual Congress: Hematologic Malignancies™ sponsored by the National Comprehensive Cancer Network® (NCCN¨). The first of the NCCN...
Study Finds Quality of Physician Recommendation to Parents Key to Encourage/Discourage HPV Vaccination of Adolescents
A nationwide online survey of 776 pediatricians and family physicians assessing the quality of their human papillomavirus (HPV) vaccine recommendations to parents has found that approximately 27% of respondents said they do not strongly endorse HPV vaccination; further, 26% and 39% of respondents...
Expert Point of View: William J. Gradishar, MD, FASCO
Discussant of the Neoadjuvant Breast Symphony Trial data, William J. Gradishar, MD, FASCO, Betsy Bramsen Professor of Breast Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, underscored the importance of identifying patients in a more precise and...
Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer
The antibody-drug conjugate rovalpituzumab tesirine has shown strong clinical activity as second- and third-line treatment for small cell lung cancer in a phase I/Ib multicenter study,1 especially in the subset with high expression of the delta-like protein 3 (DLL3), which the drug targets. This...
Expert Point of View: Martin Reck, MD, PhD
Martin Reck, MD, PhD, Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf in Germany, discussed the study at the Presidential Session, calling it “very important work.” This study shows that, with more sensitive assays, T790M mutations are much more frequent than previously ...
Combined EGFR and VEGF Inhibition Ameliorates the Impact of the EGFR T790M Mutation in NSCLC
Treatment with erlotinib and bevacizumab (Avastin) may help overcome the poor prognosis associated with T790M mutations present at diagnosis in advanced non–small cell lung cancer (NSCLC), according to the results of the phase II BELIEF trial.1 At the 2015 European Cancer Congress, Rolf A. Stahel,...
Expert Point of View: Fabrice André, MD, PhD, and Peter Naredi, MD, PhD
In discussing the findings of this study on genetic sequencing of breast cancer tissue, Fabrice André, MD, PhD, of the Gustave Roussy Institute, in Villejuif, France, questioned whether all the genes that were found to be enriched in the relapsed samples were driving the relapse and whether any...
Primary vs Metastatic Breast Cancer: The Genetic Landscape Varies
Breast tumors that recur appear to have a different genetic profile than those that do not, and they often demonstrate targetable mutations, according to the largest study of genetic sequencing of breast cancer tissue to date.1 This finding was presented at the 2015 European Cancer Congress. “We...
PD-1/PD-L1 Inhibitors Show Promise in Additional Tumor Types
While inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1) are becoming established in melanoma, non–small cell lung cancer, and renal cell carcinoma, their efficacy is also being evaluated in numerous other tumor types, with promising results, according to studies presented...
Expert Point of View: Bertrand Tombal, MD, PhD
We have made major progress by moving docetaxel forward, and now the largest pool of patients who become hormone resistant have received local therapy and then progressed. We have a lot of drugs for castration-resistant prostate cancer, and we are studying them earlier in the course of disease, but ...
Update on Clinical Trials in Metastatic Prostate Cancer
Despite the proliferation of new drugs to treat prostate cancer, further progress is proving somewhat elusive, according to three trials presented at the 2015 European Cancer Congress. One study had positive results with orteronel maintenance therapy in patients with metastatic castration-resistant ...
Expert Point of View: Ronald de Wit, MD, PhD
Ronald de Wit, MD, PhD, of Erasmus Medical Center, Rotterdam, Netherlands, called the use of docetaxel in addition to androgen-deprivation therapy “the latest paradigm shift” in the treatment of prostate cancer. The data showing a 10% absolute improvement in survival in the metastatic setting “are...
Meta-analysis Evaluates Benefit of Docetaxel and Bisphosphonates in Hormone-Sensitive Prostate Cancer
The results of a meta-analysis conducted in the United Kingdom may guide clinicians in the use of docetaxel and bisphosphonates in patients with hormone-sensitive prostate cancer.1 Claire L. Vale, PhD, Senior Research Scientist at the Medical Research Council Clinical Trials Unit at University...
Cooperative Group Study Finds Radiation May Benefit Patients With Atypical Meningiomas
Management of the vast majority of meningiomas is straightforward, but treatment of atypical meningiomas has been controversial. Should radiation be part of therapy or not has been the question. The first analysis of Radiation Therapy Oncology Group (RTOG) 0539 suggested that patients will have...
Debate Over Physician-Assisted Suicide Continues, State by State
In 1997, after surviving a storm of high-court legal challenges, Oregon’s Death With Dignity Act went into effect, making Oregon the first American state to legalize physician-assisted suicide. The Supreme Court ruled that there was no right to assisted suicide in the Constitution but implied that...
Is Health Care in the United States a Basic Human Right or an Entitlement?
Mercy Killers is a one-man show that details the consequences of a medical health-care catastrophe (breast cancer) in a family.1 This disturbing fictional account is actually a daily event in cancer centers: losing insurance for technicalities, losing a home because of an inability to pay the...
